Form 4 for CDT CDT Equity Inc.
Accepted 2025-09-22 00:00:00 ET · period of report 2025-09-19 · accession 0001493152-25-014477 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-22 | 2025-09-19 | CDT | Regan Andrew | CEO, Dir, 10% | A - Grant | $0.69 | +1.12M | 1.12M | +2,545,455% | +$772.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-19 | A | A | 1,120,000 | $0.69 | 1,120,044 | D | — | — | (F1) On September 19, 2025, CDT Equity Inc. (formerly known as Conduit Pharmaceuticals Inc. (the "Issuer")) granted Dr. Andrew Regan ("Dr. Regan") 1,120,000 shares of common stock, par value $0.0001 ("Common Stock"), of the Issuer pursuant to the Issuer's Amended and Restated 2023 Stock Incentive Plan as compensation for his services as a director and an officer of the Issuer. (F2) Based on the closing price per share of Common Stock on September 18, 2025. |